By Justin Yamashita, MSc. Benchtop, site, CRO: three levels of basic and clinical research, explained without spin.
From Issue 015
Last issue, that long list of side effects at the end of a drug commercial turned out to be a receipt, proof of everything the drug had to demonstrate. This issue, meet the products on the other shelf that borrow a drug’s power without the receipt.
From the bench
On Tuesday we took two of Jay’s bottles to a lab and watched a scientist measure what was actually inside. The reveal: no one had to run that test before he bought them. This is the plain version of what the machine showed.
Nature’s Ozempic, and the bottle that is secretly a statin
Two examples make the whole thing click.
The first is berberine, sold all over social media as nature’s Ozempic.
The second is red yeast rice, sold as a gentle, natural way to lower cholesterol. Both are marketed as the kinder, plant-based version of a prescription. Both reveal the same trick.
Myth: Naturella at play, marketing them as natural, so gentler and safer than the prescription drug they resemble.
The paradox at the center of the supplement aisle
Here’s the part that cuts through almost every natural-version claim. If a supplement is strong enough to actually work like a drug, then it’s strong enough to act like one, with the same risks and interactions. If it is so gentle that it needs no caution at all, then it probably is not doing much. You do not get to have it both ways. Power and consequences come together.
This is why your doctor and pharmacist should know, and you can fill them in with the full picture by keeping one of these medication and supplement logs.
Berberine is not Ozempic
Berberine does have some effect on blood sugar, but it works mainly through an enzyme (a tiny helper in your body that speeds up important jobs like breaking down food) called AMPK, closer to how metformin works than to how Ozempic works. It is not the same molecule, it does not act on the same target (the GLP-1 receptor), and the human evidence behind it is far smaller and shorter. A 2025 review that pooled the randomized trials found berberine modestly improved a few markers, triglycerides, fasting glucose, waist size, and BMI, with a safety record no worse than placebo. Modest and real is not the same as nature’s Ozempic. That name sells a sameness that does not exist. [1]
Red yeast rice is the cleanest example of all
Red yeast rice naturally contains a compound called monacolin K. Monacolin K is chemically the same as lovastatin, a prescription statin.
Both bottles have lovastatin.
So a bottle labeled natural cholesterol support can contain an actual statin, except the dose is not controlled and can vary widely from one bottle to the next, and unless you tell your doctor and pharmacist you are taking it, you could end up doubling up on anti-cholesterol medications. When researchers tested 28 store-bought brands, the monacolin K swung more than 60-fold between them, and none of the labels listed the amount because they are proprietary formulas. Some red yeast rice has also been found to contain citrinin, a mold byproduct that can harm the kidneys. [2][3][4]
What safe actually means
People push back here by saying that the prescription is not safe either, look at that side effect list. But that list is not a warning that the drug is dangerous. It is the record of what happened during the clinical trials, measured, at a known dose, in real people, with every case deliberated to decide whether it could be related to the drug. If it could not be ruled out, it stayed on the list. Safe was never a promise that nothing can go wrong. Nothing you put in your body works the same in everyone, because no two bodies are the same. Safe means known and watched: known dose, known risks, known manufacturing, and someone tracking how it affects you. The supplement is not the safe choice or the dangerous one. It is the unmeasured one. You are trading known for unknown.
Justin here, your friendly oncology clinical project manager, full time skeptic. I’ve sat on the other side of that side effect list. In clinical research, from the benchtop to the trial site to the CRO, every one of those effects was measured at a known dose and judged for cause by a real person, often by me, on a deadline. That paperwork is the receipt a supplement never has to produce.
This is where Issue 014 comes back
If you take red yeast rice on top of a prescription statin, you may be doubling the same drug. If you take berberine with a diabetes medicine, the effects can stack. Your doctor or pharmacist cannot catch what they do not know you take. The natural label is exactly what makes people leave it off the list.
What You Can Do
Simple rule: if a supplement claims to do what a drug does, treat it like a drug. If you do not know, add it to the list anyway. Ask the same questions, and put it on the list you bring to your doctor. Natural is a description of where something came from, not a promise about what it does to you.
Three red flags for any health claim, not just these two:
1. It borrows a prescription drug’s name (nature’s version of a real medicine).
2. It leans on the word natural to mean safe.
3. It promises a drug’s result with none of a drug’s cautions.
When you see all three, you are looking at a costume, the exact tactic named in this week’s Black Box Warning.
Running the Skeptic’s Toolkit (the same questions Sam asked at the bench)
Get the deck of questions: A Skeptic’s Toolkit — 10 Questions for Any Claim
Q4, Who funded this, and do they have a stake in the answer? The seller profits whether or not it works, and they got to skip the test that would have proven it.
Q5, Am I applying the same standards to all claims? A prescription statin had to prove its identity and dose before approval. Red yeast rice is the same molecule and proved neither. Hold both to the same bar.
Q8, How many people were studied, and has this been replicated? For the prescription, you can answer. For berberine as nature’s Ozempic, the human evidence is small and short. For the dose inside a red yeast rice bottle, it changes batch to batch. We will tackle a sample size of one (n = 1 is how the biostatisticians write it) with Dr. Anecdote another day.
And the one question that catches the whole costume: what is actually in it, and who checked the dose? Ask it of either bottle and the costume falls off.
This Week in The Informed
The web edition goes under the hood: why monacolin K and lovastatin are the same molecule under two different rulebooks, how the AMPK pathway makes berberine nothing like a GLP-1 drug, why no premarket test was required, and what safe means in pharmacology, including why the same dose lands differently in different people. Read it at roottorx.com.
Next Issue
Next we follow the logic to its strangest place: peptides. People who fear an approved, regulated medicine, while injecting a research chemical labeled not for human consumption. It is timely too. The FDA is reviewing these compounds right now. That is Issue 017, The Peptide Paradox.
New Reader Path
New here? Start with three: 003b, the Skeptic’s Toolkit. 001, why we distrust. 004, how a drug is made.
References
[1] Liu D, Zhao H, Zhang Y, Hu J, Xu H. Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials. Frontiers in Pharmacology. 2025;16:1572197.
[2] Cohen PA, Avula B, Khan IA. Variability in strength of red yeast rice supplements purchased from mainstream retailers. European Journal of Preventive Cardiology. 2017;24(13):1431 to 1434.
[3] National Center for Complementary and Integrative Health (NIH). Red Yeast Rice. nccih.nih.gov/health/red-yeast-rice
[4] U.S. FDA determination that red yeast rice products containing more than trace monacolin K are unapproved new drugs (Pharmanex v. Shalala, upheld 2001).
Want Thursday and Friday too?
The Informed (Thursday) and The Verdict (Friday) do not come automatically. You have to turn them on yourself. It takes ten seconds and it is the only way the full week lands in your inbox.
Know someone about to fall for this? Hand them the antidote. Refer and collect the Series 1 cards.
You are receiving this because you subscribed at roottorx.com.
Disclosure: Root to Rx is published independently by Open Label Media LLC. Views expressed are personal views of Justin Yamashita and do not represent his employer or any affiliated organization. No employer resources or proprietary information are used. Every claim is sourced from publicly available materials.
Root to Rx | 228 Park Ave S, #29976, New York, New York 10003, United States